Acacetin, a naturally occurring flavonoid, has attracted increasing attention due to its broad anticancer potential. In vitro and in vivo studies using diverse tumor models have demonstrated that acacetin modulates oncogenic signaling, suppresses angiogenesis, and induces apoptosis and other regulated cell death pathways. With the rising demand for multi-target therapeutics, network pharmacology and molecular docking have emerged as powerful tools to unravel the complex molecular mechanisms of phytochemicals. Unlike previous reviews that have mainly focused on single pathways or limited cancer contexts, this review emphasizes novelty by integrating network pharmacology with molecular docking and explicitly linking these computational predictions to experimental validation, thereby identifying epidermal growth factor receptor (EGFR), signal transducer and activator of transcription 3 (STAT3), and the serine/threonine kinase AKT (also known as protein kinase B (PKB) as central experimentally supported targets. This integrative framework maps acacetin’s multi-target anticancer mechanisms and clarifies its translational opportunities for future therapeutic development.
Building similarity graph...
Analyzing shared references across papers
Loading...
Jung Yoon Jang
Donghwan Kim
Eunok Im
International Journal of Molecular Sciences
Pusan National University
Korea Food Research Institute
Hyoja Geriatric Hospital
Building similarity graph...
Analyzing shared references across papers
Loading...
Jang et al. (Fri,) studied this question.
www.synapsesocial.com/papers/68d9051441e1c178a14f4ade — DOI: https://doi.org/10.3390/ijms26199433
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: